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Summary 
We report the identification of Iigands for Tyro 3 (alter- 
natively called Sky, rse, brt, or tit) and Axl (alterna- 
tively, Ark or UFO), members of a previously orphan 
family of receptor-like tyrosine kinases. These ligands 
correspond to protein S, a protease regulator that is 
a potent anticoagulant, and Gas6, a protein related to 
protein S but lacking any known function. Our results 
are reminiscent of recent findings that the procoagu- 
lant thrombin, a protease that drives clot formation 
by cleaving fibrinogen to form fibrin, also binds and 
activates intracellular signaling via a G protein-coupled 
cell surface receptor. Proteases and protease regula- 
tors that also activate specific cell surface receptors 
may serve to integrate coagulation with associated cellu- 
lar responses required for tissue repair and growth, 
as well as to coordinate protease cascades and associ- 
ated cellular responses in other systems, such as those 
involved in growth and remodeling of the nervous 
system. 
Introduction 
An important class of cell surface receptors are those with 
intrinsic protein-tyrosine kinase activity, thus known as re- 
ceptor tyrosine kinases (RTKs) (Schlessinger and UIIrich, 
1992). Binding of the extracellular portion of an RTK to 
its cognate polypeptide ligand results in receptor dimeriza- 
tion or oligomerization, which in turn activates the intracel- 
lular catalytic domain of the receptor, resulting in tyrosine 
phosphorylation of the receptor as well as of multiple intra- 
cellular signaling molecules. These molecules initiate a 
variety of signaling cascades that determine the wide vari- 
ety of phenotypic responses that can be mediated by 
RTKs. Thus, the insulin receptor is critical for maintaining 
glucose homeostasis and is a major regulator of metabo- 
lism in many cell types; receptors for vascular endothelial 
growth factor appear to be critical for angiogenesis; and 
the Trk receptors for the neurotrophins mediate survival 
and differentiation effects upon particular neurons (Schles- 
singer and UIIrich, 1992). 
The extensive sequence similarity shared by tyrosine 
kinase domains has allowed for homology-based cloning 
of a large number of proteins that appear to be RTKs, in 
that they are predicted transmembrane proteins with large 
ectodomains and a cytoplasmic tyrosine kinase domain 
(e.g., Lai and Lemke, 1991). These proteins have been 
designated as orphan RTKs because their presumed li- 
gands have yet to be identified. Recent progress has al- 
lowed for the identification of ligands for previously orphan 
RTKs. For example, a receptor-based affinity purification 
approach (Bartley et al., 1994), as well as receptor-based 
detection screens for ligand-expressing cells in pools of 
cells randomly transfected with cDNA expression libraries 
(Beckmann et al., 1994; Cheng and Flanagan, 1994; Davis 
et al., 1994), has yielded several related ligands for what 
had previously been the largest family of orphan RTKs, 
those related to Eph and Eck. Here we have focused on 
the identification of ligands for another family of previously 
orphan receptor-like tyrosine kinases. This family was first 
recognized when a search for receptor-like tyrosine ki- 
nases in the rat nervous system yielded DNA fragments 
encoding portions of three candidate receptor-like tyrosine 
kinases that appeared to be closely related to each other 
(Lai and Lemke, 1991); these candidate receptor-like tyro- 
sine kinases were designated Tyro 3, Tyro 7, and Tyro 
12. Full-length versions of cDNAs encoding these three 
receptor-like tyrosine kinases have now been character- 
ized: Tyro 3 has also been named Sky, rse, brt, or tif (Lai 
et al., 1994; Ohashi et al., 1994; Mark et al., 1994; Fujimoto 
and Yamamoto, 1994; Dai et al., 1994); Tyro 7 has also 
been designated Axl, UFO, or Ark (O'Bryan et al., 1991; 
Janssen et al., 1991; Rescigno et al., 1991; Bellosta et 
al., 1995); what is likely the chicken version of Tyro 12 
has been called Eyk (Jia and Hanafusa, 1994), while the 
human form has been dubbed c-Mer (Graham et al., 1994). 
These three related receptor-like tyrosine kinases display 
differential patterns of expression. Tyro 31Skylrselbrtltif 
(hereafter called Tyro 3) is most prominently expressed 
in the adult nervous system, although it is notably ex- 
pressed in some nonneural tissues such as kidney, ovary, 
and testis, and it is also found in a number of hematopoietic 
cell lines. AxI/UFO/Ark (hereafter called Axl) and Tyro 121 
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Eyk/Mer (hereafter called Mer) are also expressed in the 
nervous system, but are more widely expressed than Tyro 
3 in peripheral tissues. All three of these related receptor- 
like tyrosine kinases have similar ectodomains, sharing 
about 35% amino acid identity and consisting of two immu- 
noglobulin-like domains followed by two fibronectin type 
III repeats, suggesting that they recognize related ligands. 
We have utilized receptor-based detection and affinity 
purification approaches to identify ligands for Tyro 3 and 
Axl. These ligands correspond, respectively, to a pre- 
viously identified protein, designated protein S (Dahlback, 
1991), known for its potent anticoagulant actions, and a 
protein S relative known as Gas6 (Manfioletti et al., 1993) 
because it was cloned as a growth arrest-specific gene. 
The critical anticoagulant role of protein S is most dramati- 
cally revealed by the massive thrombotic complications 
suffered by infants homozygous for protein S deficiency 
(Mahasandana et al., 1990; Pegelow et al., 1992). Protein 
S seemingly acts by indirectly inhibiting proteases in- 
volved in the coagulation cascade, although the precise 
mechanism by which protein S mediates this inhibition 
remains unclear (Dahlback, 1991); several additional func- 
tions for protein S, not directly involving coagulation, have 
also been proposed (Hessing, 1991; Gasic et al., 1992; 
Maillard et al., 1992; Phillips et al., 1993). Protein S is a 
heavily modified -70  kDa protein that contains several 
modules, an N-terminal region containing vitamin K-depen- 
dent .y-carboxylation sites, a thrombin-sensitive module, 
a series of epidermal growth factor (EGF)-Iike repeats that 
undergo hyroxylation modification, and a module with ho- 
mology to steroid-binding lobulin (Dahlback, 1991). Al- 
though nothing is known about the function of Gas6, it 
shares all but the thrombimsensitive module with protein 
S (Manfioletti et al., 1993). 
While our findings that protein S-related proteins are 
ligands for the Tyro 3/Axl family of RTKs were quite unex- 
pected, they are reminiscent of recent findings with an- 
other protein critical for regulating coagulation, the proco- 
agulant thrombin, which is a protease that drives clot 
formation by cleaving fibrinogen to form fibrin. Thrombin, 
like protein S, has also been found to bind and activate 
intracellular signaling via a specific cell surface receptor; 
in the case of thrombin, however, the receptor is a G pro- 
tein-coupled receptor (Vu et al., 1991; Coughlin, 1993). 
These thrombin receptors may be involved in regulating 
coagulation pathways or related processes (Coughlin, 
1993), but it has also been suggested that they act to 
regulate thrombin involvement in other protease cas- 
cades, such as those involved in remodeling of the ner- 
vous sytem (Monard, 1993); thrombin receptors also medi- 
ate more traditional growth factor-like actions of thrombin 
(Coughlin, 1993). It seems quite remarkable (and perhaps 
not coincidental) that a procoagulant/protease (thrombin) 
and an anticoagulant/protease r gulator (protein S) would 
both have the ability to activate intracellular signaling cas- 
cades via specific cell surface receptors. The realization 
that the protein S-related proteins are ligands for the Tyro 
3/Axl family of RTKs will likely provide new insights into 
the regulation of coagulation and adjunctive systems nec- 
essary for tissue repair and growth, as well as unrelated 
systems that also exploit both these factors and their re- 
ceptors. 
Results 
Identification of an Activity That Binds and Induces 
Autophosphorylation of Tyro 3 
To identify a source of a ligand for Tyro 3, we evaluated 
concentrated conditioned media from a number of differ- 
ent cell lines for their ability to induce tyrosine phosphory- 
lation of the Tyro 3 receptor expressed in Rat2 fibroblasts. 
Only a small number of the cell lines conditioned in serum- 
free media displayed Tyro 3-phosphorylating activity, the 
most notable being the ABAE bovine endothelial cell line 
(Figure 1A, left). In contrast, all conditioned media pre- 
pared in serum displayed prom inent Tyro 3-phosphorylat- 
ing activity, suggesting that serum itself was a source of 
this activity. Consistent with this possibility, evaluation of 
fetal bovine serum (FBS) revealed that it alone contained 
notable levels of Tyro 3-phosphorylating activity (Figure 
1A, left); various batches of 10-fold concentrated ABAE 
conditioned medium contained activity at a concentration 
comparable to that found in 1%-3% serum (e.g., Figure 
1A; data not shown). 
If the Tyro 3-phosphorylating activity present in serum 
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Figure I. Tyro 3 Phosphorylation-lnducing and Binding Activity Is 
Identified in Conditioned Medium from ABAE Cells and in FBS 
(A) ABAE conditioned medium (10-fold concentrated) and FBS (at indi- 
cated concentrations) induce Tyro 3 tyrosine phosphorylation that is 
blocked in the presence of excess soluble Tyro 3-Fc. Rat2 fibroblasts 
transfected with an expression vector encoding mouse Tyro 3 were 
challenged for 5 rain with indicated samples, then analyzed for levels 
of tyrosine-phosphorylated Tyro 3 as described in the Experimental 
Procedures; in indicated lanes, FBS was premixed with 50 l~glml of 
either soluble Tyro 3-Fc or soluble TrkB-Fc prior to being added to 
the reporter cells. 
(13) BIAcore assay of Tyro 3-binding activity. The indicated samples of 
ABAE conditioned medium (10-fold concentrated) orFBS were passed 
over a BIAcore sensor chip surface that had Tyro 3-Fc covalently 
coupled to it; prior to being passed over the sensor chip, samples 
were in some cases premixed with 10 l~glml soluble Tyro 3-Fc (sol. 
Tyro 3) or TrkB-Fc (sol. TrkB), as indicated. Binding to the sensor 
chip surface is indicated (as RUe). 
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or in ABAE conditioned medium were a bona fide Tyro 3 
ligand that directly bound to the Tyro 3 ectodomain and 
thus activated catalytic activity of the Tyro 3 endodomain, 
we reasoned that excess amounts of a soluble Tyro 3 ecto- 
domain would act as a blocker of this activity by binding 
to it and preventing its interaction with cell surface Tyro 
3 receptors. To evaluate this possibility, we constructed 
a fusion between the ectodomain of Tyro 3 and the Fc 
portion of human immunoglobulin G1 (designated soluble 
Tyro 3 or Tyro 3-Fc), as previously described for the Eph- 
related receptors (Davis et al., 1994); we also constructed 
as a control a similar Fc fusion for the TrkB receptor (desig- 
nated soluble TrkB or TrkB-Fc). This soluble form of Tyro 
3, but not the soluble form of TrkB, effectively blocked the 
ability of serum (Figure 1A, right) or ABAE conditioned 
medium (data not shown) to induce phosphorylation of the 
full-length Tyro 3 expressed in Rat2 cells. Thus, serum 
and ABAE contain an activity that appears to behave like 
a bona fide Tyro 3 ligand in that it specifically binds to the 
ectodomain of Tyro 3 and induces Tyro 3 phosphorylation. 
To measure directly binding of this activity to the ecto- 
domain of Tyro 3, we purified recombinant soluble Tyro 
3-Fc and covalently coupled it to the dextran surface of 
a BIAcore sensor chip and used the BIAcore (Johnsson 
et al., 1991; Fagerstam, 1991) to quantitate binding to this 
Tyro 3 surface; specific binding to the Tyro 3 immobilized 
on the surface was assessed by comparing binding in the 
presence or absence of excess soluble Tyro 3-Fc or solu- 
ble TrkB-Fc. Different batches of 10-fold concentrated 
ABAE conditioned medium exhibited specific Tyro 3-bind- 
ing activity approximately equivalent o that found in 1%- 
3% serum (e.g., Figure 1B; data not shown). 
Tyro 3-Binding Activity Also Mediates Tyro 
3-Dependent Growth Responses 
To determine whether the Tyro 3-binding and Tyro 3 phos- 
phorylation-inducing activity was also capable of mediat- 
ing Tyro 3-dependent biological responses, we first gener- 
ated NIH 3T3 fibroblasts tably expressing full-length Tyro 
3 receptors. These cells exhibited enhanced growth re- 
sponsiveness to serum, as would be expected if the 
transfected Tyro 3 was mediating a gain of responsiveness 
to an abundant growth factor present in serum (Figure 2A, 
left); this assay was, however, complicated by the fact that 
the parental NIH 3T3 cells responded quite well to factors 
other than the Tyro 3 ligand, such as platelet-derived 
growth factor, normally found in serum. To accentuate 
differences between the serum responsiveness of paren- 
tal and Tyro 3-expressing NIH 3T3 cells, we utilized a 
different assay, in which parental NIH 3T3 cells do not 
normally respond. In low concentrations of serum, NIH 
3T3 cells normally undergo growth arrest and do not ap- 
pear morphologically transformed. The Tyro 3 receptor 
has previously been shown to have transforming capabili- 
ties (Lai et al., 1994), so we reasoned that if serum did 
indeed contain abundant levels of a functional Tyro 3 li- 
gand, Tyro 3-expressing NIH 3T3 cells might differ from 
parental NIH 3T3 cells in that they would become morpho* 
logically transformed in low concentrations of serum. To 
evaluate this possibility, NIH 3T3 cells were transfected 
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Figure 2. Tyro 3 Ligand Identified in Serum Can Induce Biological 
Responses Mediated by Tyro 3 
(A) NIH 3T3 and BAF cells expressing Tyro 3 display enhanced growth 
responses to serum. Either parental cells or transfectants expressing 
introduced vectors encoding mouse Tyro 3 or the chimeric Tyro 3-TrkC 
receptors were plated in increasing concentrations of FBS, as indi- 
cated. After 3 days, cell number was evaluated by use of an M'IT 
assay (see Experimental Procedures). 
(B) Tyro 3-transfected NIH 3T3 cells are transformed by low concentra- 
tions of serum. NIH 31"3 cells were transfected with expression vectors 
encoding the indicated receptors and then selected in the indicated 
concentrations of serum (in some cases supplemented with EGF). 
Number of morphologically transformed foci that developed in these 
cultures is indicated. 
with a Tyro 3 expression vector and selected in medium 
containing low (0%-3%) concentrations of serum; foci of 
morphologically transformed fibroblasts grew out (Figure 
2B), indicating that serum does indeed have a ligand that 
activates the Tyro 3 receptor. In contrast, neither parental 
NIH 3T3 cells nor NIH 3T3 cells transfected with a vector 
encoding the EGF receptor (EGFR) yielded transformed 
foci in low serum (serum does not contain EGF), although 
foci were formed as expected when the serum was sup- 
plemented with EGF (Figure 2B). To rule out the remote 
possibility that the Tyro 3 receptor catalytic domain was 
promoting transformation in a serum-dependent yet ligand- 
independent fashion, we constructed a vector encoding 
a chimeric receptor in which the ectodomain of the EGFR 
was fused to transmembrane and cytoplasmic domains 
of the Tyro 3 receptor (designated EGFR-Tyro 3). Fibro- 
blasts transfected with this chimeric receptor did not yield 
transformed foci when grown in low serum, but did when 
grown in the presence of EGF (Figure 2B). 
To develop another convenient assay that would be able 
to detect the presence of a functional Tyro 3 ligand in 
serum, we utilized the interleukin-3 (IL-3)-dependent BAF-3 
cell line, which normally does not respond to serum; trans- 
fection of certain, but not all, RTKs into the BAF-3 cells 
allows them to exhibit growth responses to the ligand spe- 
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cific for the introduced RTK (Collins et al., 1988). EGFR- 
Tyro 3 introduced into BAF-3 cells did not allow these cells 
to grow in the presence of EGF, presumably because the 
Tyro 3 cytoplasmic domain does not activate signaling 
pathways that elicit growth in BAF-3 cells; this inability 
to promote BAF-3 growth responses has previously been 
seen with some receptors, whereas others, such as the 
Trk receptors, efficiently mediate growth in BAF-3 cells 
(data not shown). Thus, we constructed a chimeric recep- 
tor in which the ectodomain of the Tyro 3 receptor was 
fused to the cytoplasmic domain of TrkC, which we pre- 
sumed would allow the Tyro 3 ligand to promote growth 
responses in BAF-3 cells. BAF-3 cells expressing the chi- 
meric Tyro 3-TrkC receptor, in contrast with parental 
BAF-3 cells, did indeed display dose-dependent growth 
responses to serum (Figure 2A, right). The chimeric Tyro 
3-TrkC receptor also proved more potent han the parental 
Tyro 3 receptor in NIH 3T3 assays (data not shown) and 
thus was substituted for the parental Tyro 3 receptor in 
NIH 3T3 assays presented below. 
Receptor-Based Affinity Chromatography Identifies 
Protein S as a Tyro 3 Ligand 
All together, the above data indicate that both ABAE condi- 
tioned medium and FBS contain a ligand that binds the Tyro 
3 ectodomain and induces Tyro 3 tyrosine phosphorylation 
as well as Tyro 3-mediated biological responses. To iso- 
late this ligand, we took advantage of the fact that it could 
bind to the ectodomain of Tyro 3. FBS ( -  450 mg of total 
protein) was directly loaded onto a column containing im- 
mobilized Tyro 3-Fc. After extensive washing (in buffer 
containing 0.5 M NaCI), material ( -  7.5 I~g) eluted by using 
10 mM glycine, 250 mM NaCI at pH 2.5 exhibited highly 
enriched binding to Tyro 3 (starting material contained 
0.657 resonance units [RUs] of Tyro 3 binding per micro- 
gram, while purified material contained 13,900 RUs/p.g, 
corresponding to a ~21,000-fold purification) as deter- 
mined via the BIAcore. SDS-polyacrylamide gel electro- 
phoresis (SDS-PAGE) analysis revealed a single major 
band with a molecular mass of -75  kDa (Figure 3A); se- 
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Figure 3. Receptor-Based Affinity Purification of Protein S as the Li- 
gand for Tyro 3 
(A) SDS-PAGE analysis depicts eluate from Tyro 3 affinity column, 
revealing a major species of -75 kDa. 
(13) Tryptic peptide sequences obtained from major - 75 kDa species 
indicated in (A) (see Experimental Procedures) correspond to portions 
of the bovine protein S sequence. 
quence analysis of peptides resulting from tryptic diges- 
tion of electroblotted proteins in this band revealed se- 
quence identity with a previously characterized protein, 
the anticoagulation factor protein S (Figure 3B). 
Confirmation That Protein S Is a Functional 
Ligand for Tyro 3 
Because protein S is an abundant serum protein with a 
previously characterized function as an anticoagulation 
factor, it seemed imperative to verify independently and 
definitively that it acted as a bona fide ligand for Tyro 3. 
Thus, we confirmed the ability of recombinant protein S 
to activate Tyro 3: conditioned medium from COS cells 
transfected with a vector encoding human protein S (pro- 
ducing nanomolar levels of protein S), but not conditioned 
medium from COS cells transfected with a control vector, 
was very effective at inducing Tyro 3 tyrosine phosphoryla- 
tion (Figure 4A) and Tyro 3-dependent growth (Figure 4B) 
in reporter cells. 
A 
Tyro3.£~ 
Phosph, 
u~ u3 
~Ss8S 
B ~BAF3 ~ BAF3- 
. . . .  ~ ~ Tyro3/TrkC 
E 
c~ 
d 
"~ kC O So % kc 
C 125q 112 
;do o I!la 
L 'T +~j 
DNA Transfected: 
Figure 4. Recombinant Human Protein S Induces Tyro 3-Mediated 
Responses 
(A) Recombinant protein S induces Tyro 3 phosphorylation. Condi- 
tioned medium from mock-transfected (10-fold concentrated) COS 
cells or from COS cells expressing a transfected human protein S 
expression vector (either 2-fold or 10-fold concentrated, shown by im- 
munoblotting tocontain the indicated concentrations, either -0.6 nM 
or -3  nM, of human protein S) induced tyrosine phosphorylation f 
Tyro 3 in Rat2 reporter cells. 
(13) Recombinant protein S specifically supports BAF-3 cells express- 
ing Tyro 3 receptor chimera. Parental BAF-3 cells or the Tyro 3-reporter 
BAF-3 transfectants described in Figure ?_A were cultured in the pres- 
ence of the indicated concentration fconditioned medium from either 
mock-trasnfected COS cells, COS cells expressing human protein S, 
or ABAE cells. The concentrations of protein S in the various amples, 
as assayed by immu noblotting for protein S, are indicated. After 3 days, 
cell number was evaluated by use of an MTT assay (see Experimental 
Procedures). 
(C) Cotransfection ofvectors encoding human protein S and a mouse 
Tyro 3 chimera results in vitamin K-dependent autocrine transforma- 
tion of NIH 3T3 cells; quantitation ofloci obtained is depicted. 
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We also demonstrated that protein S could collaborate 
with Tyro 3-TrkC to transform NIH 3T3 cells autocrinely: 
individual transfections of NIH 3T3 cells with either a vec- 
tor encoding protein S or a vector encoding Tyro 3-TrkC 
did not yield transformed foci when the cells were plated 
in the absence of serum, although cells cotransfected with 
both protein S and Tyro 3-TrkC yielded large numbers of 
transformed loci (Figure 4C). Since protein S production 
requires y-carboxylation mediated by a vitamin K-depen- 
dent carboxylase (Dahlback, 1991), we also performed the 
cotransfections in the absence of vitamin K and found 
greatly reduced numbers of foci, consistent with the foci 
formation requiring production of vitamin K-dependent 
protein S (Figure 4C). All together, the genetic evidence 
confirms the results of the affinity purification and demon- 
strates that protein S is a functional igand for the Tyro 3 
receptor. 
Identification of Protein S-Related Gas6 
as a Ligand for Axl 
The surprising finding that protein S is a ligand for the 
Tyro 3 receptor would suggest that other Tyro 3-related 
receptors, such as Axl, would similarly bind to protein S 
or perhaps to protein S-related ligands. Defining such a 
l igand-binding specificity for Axl would in turn further verify 
the assignment of protein S as a functionally relevant li- 
gand for Tyro 3. To attempt identification of a ligand for 
Axl, we constructed a vector encoding a chimeric protein 
in which the ectodomain of Axl was fused to the Fc portion 
of human immunoglobulin G1, as we had previously done 
for Tyro 3. The chimeric AxI-Fc protein produced from this 
vector was purified and covalently coupled to the dextran 
surface of a BIAcore sensor chip and used to screen for 
binding activities in serum and a panel of conditioned me- 
dia. In contrast with the situation with Tyro 3, little or no 
binding activity specific for Axl was detected in serum. 
However, large amounts of a specific binding activity, as 
judged by its competition by excess soluble AxI-Fc, was 
detected in the conditioned media of several cell lines. 
Interestingly, ABAE cells, which had displayed prominent 
Tyro 3-binding activity, also displayed notable specific 
binding to Axl. The Tyro 3-binding activity in ABAE cells 
appeared distinct from the Axl-binding activity in the same 
cells, since excess soluble Tyro 3-Fc could almost com- 
pletely compete the binding activity specific for the Tyro 
3 surface but only marginally compete the binding activity 
specific for the Axl surface, while excess soluble AxI-Fc 
had essentially the reciprocal competition profile (Fig- 
ure 5A). 
Having defined a source of a specific Axl-binding activ- 
ity, we once again took advantage of a receptor-based 
affinity purification approach. We loaded 10-fold concen- 
trated ABAE conditioned medium ( -  2250 mg of total pro- 
tein) directly onto a column containing immobilized Axl-  
Fc. After extensive washing (in buffer containing 0.5 M 
NaCI), material ( -28  pg) eluted by using 10 mM glycine, 
250 mM NaCI at pH 2.5 exhibited highly enriched binding 
to Axl (starting material contained 0.95 RUs/pg Axl bind- 
ing, while purified material contained 9723 RUs/~g, corre- 
sponding to a -10,234-fold purification) as determined 
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Figure 5. Distinct Ligands for Both Axl and Tyro 3 Can Be Found in 
ABAE Conditioned Medium 
(A) Distinct Axl- and Tyro 3-binding activities in ABAE conditioned 
medium (concentrated 10-fold). The conditioned medium was passed 
over a BIAcore sensor chip coupled to either AxI-Fc or Tyro 3-Fc; 
prior to being passed over the sensor chip, samples were in some 
cases premixed with 10 pg/ml soluble AxI-Fc (sAxl), Tyro 3-Fc 
(sTyro3), or TrkB-Fc (sTrkB), as indicated. Binding to the sensor chip 
surface is indicated (as RUs). Note that the activity binding to the Axl 
surface was only marginally competed with soluble Tyro 3-Fc, while 
the activity binding to the Tyro 3 surface was not competed by soluble 
AxI-Fc. 
(B) The affinity-purified Axl ligand (as described in Figure 6) binds 
rather specifically to Axl and not to Tyro 3; binding to Axl and Tyro 3 
surfaces and competitions with soluble Axl (sAxl) and Tyro 3 (sTyro3) 
were performed as in (A). 
(C) The affinity-purified Tyro 3 ligand (as described in Figure 3) binds 
rather specifically to Tyro 3 and not Axl; binding to Tyro 3 and Axl 
surfaces and competitions with soluble Tyro 3 (sTyro3) and Axl (sAxl) 
were performed as in (A). 
via the BIAcore. SDS-PAGE analysis revealed a single 
major band with a molecular mass of -75  kDa (Figure 
6A); sequence analysis of peptides resulting from tryptic 
digestion of electroblotted proteins in this band revealed 
marked sequence homology with a recently characterized 
relative of protein S, known as Gas6 (Figure 6B). Gas6 
has been described in mouse and human (Manfioletti et 
al., 1993). The peptide sequences we obtained from a 
bovine source (the ABAE cells) displayed 76% and 78% 
sequence identity with the corresponding regions of the 
mouse and human Gas6 proteins, respectively, while the 
mouse and human sequences were 74% identical to each 
other in these regions (Figure 6B; data not shown); in con- 
trast, the peptide sequence we obtained for the Axl ligand 
displayed only 47% identity to the corresponding regions 
of bovine protein S. Thus, the affinity-purified ligand for 
the Axl receptor appears to correspond to the bovine ver- 
sion of Gas6. 
The affinity-purified Gas6 was largely specific to Axl as 
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A B Peptide A: DGWAGR mGas6 ***G** 
bProS 143-148 S**Q*E 
Peptide B: TCQDTDEEVEGR 
mGas6232_243 ****V***QQD* 
97 bProS S*D*V***A*NL 
Peptide C: CEQVCANSPGSYTC 
68 mGas6 244.257 ***T 'V********  
bProS *A*L*V*Y**G*S* 
Peptide D: TFDPEGILFFAGGR 
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bProS *Y*S**VTLY*ESS 
Peptide E: 1AVAGDLFQLDR 
mGas6400-411 *****E****E*  
bProS *NKP*S**KPTN 
31 
Peptide F: LDGCLK 
mGas6438.443 ****MR 
bProS ****TR 
Peptide G: GSFFPGSGFAFFHLDYA 
21 raGas6474.491 *******N**TYR*N*T 
bProS **YY**T*V*Q*SIN*K 
Peptide H: HLEGSVLTFIGGLPDVPVTSAPVT 
mGas6609_632 ************************  
bProS AMKGT*V*YL* * * * ***FSAT* *N 
Figure 6. Receptor-Based Affinity Purification of Gas6 as the Ligand 
for Axl 
(A) SDS-PAGE analysis depicting eluate from Axl affinity column, re- 
vealing a major species of - 75 kDa. 
(B) Tryptic peptide sequences obtained from major - 75 kDa species 
indicated in (A) (see Experimental Procedures) compared with corre- 
sponding regions of mouse Gas6 (mGas6) as well as bovine protein 
S (bProS). Note that the purified sequence is from a bovine source 
(ABAE cells) and thus does not exactly match mouse Gas6. 
compared with Tyro 3; much more ligand bound to an Axl 
surface than to a Tyro 3 surface, and the binding was 
efficiently competed by soluble AxI-Fc but not Tyro 3-Fc 
(see Figure 5B). The affinity-purified Tyro 3 ligand (i.e., 
protein S) displayed reciprocal specificity for Tyro 3 in the 
same assays (see Figure 5C). These findings demonstrate 
that protein S and its relative Gas6 are rather specific li- 
gands for Tyro 3 and Axl, respectively. 
Northern Blot Analysis Reveals That Protein S 
mRNA Is Expressed by Cultured Schwann Cells 
and Astrocytes and Is Up-Regulated 
Following Nerve Injury 
To begin to identify physiologically relevant situations in 
which Tyro 3 might be activated by protein S, we compared 
expression of transcripts for this receptor and its ligand 
in an assortment of tissue-derived RNA samples from both 
neural and nonneural sources (Figure 7). Both Tyro 3 and 
protein S mRNAs were quite widespread in their expres- 
sion, although, as noted previously, Tyro 3 mRNA was 
more prominently expressed in the nervous system (Fig- 
ure 7A). Protein S mRNA was detected in all brain regions 
examined, but was more prominently expressed in non- 
neural tissues (Figure 7B). However, protein S was highly 
expressed in cultured Schwann cells derived from sciatic 
nerve, as well as in cultured astrocytes derived from the 
embryonic brain. In vitro cultured Schwann cells and 
astrocytes share many of the features that their in vivo 
counterparts display in response to an injury (Rudge et 
al., 1994), suggesting that protein S expression in vivo 
might be up-regulated in response to injury in either the 
peripheral or the central nervous system. Such expression 
would certainly support the notion that protein S could 
provide neurotrophic support to neurons expressing Tyro 
3 following injury or otherwise play an important role in 
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Figure 7. Northern Blot Analysis of Tyro 3 and Protein S Transcript 
Levels 
Northern blot analysis of Tyro 3 and protein Sin transcript levels in RNA 
samples derived from a variety of rat adult neural (A) and nonneural (B) 
tissues, as well as in RNA samples derived from sciatic nerve (C) 
(distal to the lesion) at various days following a crush lesion to the 
nerve, compared with cultured Schwann cells. Abbreviations: OLF, 
olfactory bulb; CTX, cortex; HIP, hippocampus; STR, striatum; THAL, 
thalamus; MBR, midbrain; HBR, hindbrain; CBL, cerebellum; SP. C, 
spinal cord; RET, retina; S. C., cultured schwann cells; ASTR, cultured 
astrocytes; DRG, isolated orsal root ganglia; SCG, isolated sympa- 
thetic ganglia; A. BR., whole adult brain; THY, thymus; SPL, spleen; 
LIV, liver; KID, kidney; LNG, lung; Sk. Mus., skeletal muscle from 
soleus muscle; HRT, heart; SKN, skin; INT, intestine; UTR, uterus; 
OVR, ovary; PLC, placenta; TST, testes. 
injury responses of Tyro 3-expressing central and periph- 
eral neurons. However, Tyro 3 mRNA was also found to 
be expressed in Schwann cells and astrocytes themselves 
(Figure 7A), raising the possibility that following injury, pro- 
tein S acts not only on neurons but on glia as well. 
To pursue the possibility that protein S was up-regulated 
in sciatic nerve in response to injury, protein S mRNA 
expression was evaluated in samples prepared from nor- 
mal sciatic nerve, as well as from sciatic nerve distal to 
a nerve lesion at 1,2, or 3 days postlesioning. This analysis 
revealed that protein S expression is clearly up-regulated 
following nerve injury (Figure 7C). 
Discussion 
The search for ligands of the Tyro 3/Axl family of RTKs 
unexpectedly revealed that protein S, a potent anticoagu- 
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Figure 8. Schematization f the Characterized and Potential Interac- 
tions between the Protein S Family of Ligands and the Tyro 3/Axl 
Family of RTKs 
lation factor, binds and activates Tyro 3, while the protein 
S-related Gas6 binds Axl. Additional Tyro 3-related re- 
ceptors, such as Mer, presumably bind either these or 
other as yet unknown members of this ligand family; simi- 
larly, these yet to be described protein S relatives could 
also bind to either Tyro 3 or Axl (Figure 8). Precise compari- 
son of receptor-ligand istributions coupled with gene dis- 
ruption studies may be required to determine which recep- 
tor-ligand pairs are relevant physiologically. 
Identification of the physiologic processes triggered by 
interactions between the Tyro 3-related receptors and 
their newly defined protein S-related ligands is an im- 
portant next challenge. The massive thrombotic omplica- 
tions suffered by infants homozygous for protein S defi- 
ciency provide dramatic evidence of the critical role of 
protein S in anticoagulation. Protein S acts as a cofactor 
for activated protein C, promoting degradation or other- 
wise inhibiting the coagulation factors Va and Villa, thus 
helping blunt further generation of thrombin (Dahlback, 
1991). However, these actions do not seem to account for 
all of the anticoagulatory activity of protein S (Dahlback, 
1991). In addition to its characterized and uncharacterized 
roles in anticoagulation, protein S has also been sug- 
gested to act in a variety of settings outside of the clotting 
system. For example, protein S interacts with a negative 
regulator of the complement cascade, C4b-binding pro- 
tein, and it has been suggested that this interaction under- 
lies potential antiinflammatory actions of protein S (Dahl- 
back, 1991; Hessing, 1991). Based on observations that 
protein S is produced by bone cells and that osteopenia 
occurs in protein S-deficient patients, it has also been 
suggested that protein S may play a role in bone turnover 
and metabolism (Maillard et al., 1992). Other studies indi- 
cate that protein S is also a mitogen for smooth muscle 
cells (Gasic et al., 1992), and production of protein S by 
neural tumor cell lines has led to the proposal that protein 
S might have some function in the brain (Phillips et al., 
1993). 
Binding and activation of Tyro 3 could clearly be involved 
in mediating or regulating any of the poorly understood 
bioactivities of protein S. It is perhaps worthwhile to con- 
sider these potential actions of protein S in the context of 
recent findings with the procoagulant hrombin, which is 
the protease that drives blood clot formation by cleaving 
fibrinogen to form fibrin. Remarkably, thrombin, like its 
indirect regulator, protein S, has also recently been found 
to bind and activate intracellular signaling via a specific 
cell surface receptor (Vu et al., 1991; Coughlin, 1993). 
This G protein-coupled receptor may in some way gauge 
levels of active thrombin, mediate the activation by throm- 
bin of platelets, or otherwise help in the regulation of throm- 
bin activity during coagulation (Coughlin, 1993). This re- 
ceptor also apparently mediates the mitogenic effects of 
thrombin on vascular smooth muscle cells (Coughlin, 
1993); such effects may occur in vivo upon exposure of 
these cells to plasma thrombin after breakdown of the 
endothelial cell barrier following physical insult or infec- 
tion. Thrombin receptors have also unexpectedly been 
found on neurons and gila in the brain (Monard, 1993), 
and these receptors may be similarly poised to detect 
breakdown of the blood-brain barrier. However, thrombin 
is also made within neural tissue, as are inhibitors of throm- 
bin protease activity (Dihanich et al., 1991; Monard, 1993). 
Furthermore, thrombin, acting via its specific G protein- 
coupled receptor, has been found to have profound mor- 
phologic effects on neurons, astrocytes, and their processes 
(Monard, 1993). These findings uggest that thrombin may 
function in brain in a manner totally independent of its 
actions during clot formation. Axon and synaptic growth 
and remodeling require the coordinated action of enzymes 
that digest the extracellular matrix together with factors 
that regulate neuronal process retraction and outgrowth. 
Thrombin is an interesting candidate to be involved in this 
coordination, since it could be part of protease cascades 
involved in remodeling of the extracellular matrix, while 
sire ultaneously activating a G-coupled receptor that would 
modulate and coordinate changes in process outgrowth 
or morphology. 
Our results now indicate that both a procoagulant/prote- 
ase (thrombin) and an anticoagulant/protease regulator 
(protein S) have the ability to activate intracellular signal- 
ing cascades via specific cell surface receptors. The many 
roles proposed for thrombin suggest related possibilities 
for protein S. Just as thrombin receptors are not activated 
by its inactive precursor (prothrombin), Tyro 3 receptors 
found in vivo could detect or respond only to a particularly 
modified form of "active" protein S and in this way act to 
gauge or to regulate (or both) some aspect of protein S 
function during coagulation. In addition, activation of cell 
surface receptors by protein S could serve to integrate 
coagulation with associated cellular responses required 
for tissue repair and growth. For example, Tyro 3 could 
be responsible for mediating the previously described abil- 
ity of protein S to induce smooth muscle cell proliferation 
(Gasic et al., 1992). If this is the case, smooth muscle cells 
in blood vessel walls might only be exposed to circulating 
protein S (as well as thrombin) after breakdown of the 
endothelial cell barrier, helping to provide an explanation 
for why endothelial injury induces the migration and prolif- 
eration of underlying smooth muscle cells that can contrib- 
ute to intimal thickening and subsequent atherosclerosis. 
Similarly, the Tyro 3 expressed by neurons in the brain 
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may gauge exposure to plasma-derived protein S follow- 
ing breakdown of the blood-brain barrier and thereby reg- 
ulate the injury response. Since neural and glial cells ex- 
press protein S, however, it is likely that the many Tyro 
3-expressing cells in the brain encounter this ligand from 
sources other than plasma and that the Tyro 3-mediated 
response of these cells to protein S is unrelated to its 
anticoagulant role in the plasma. Thus, protein S or a re- 
lated ligand could act as a classical neurotrophic factor 
for Tyro 3-expressing neurons or as a traditional growth 
factor for certain Tyro 3-expressing nonneuronal cells. At 
the same time, protein S could be involved in regulating 
protease cascades in the brain, such as those proposed 
for thrombin, that may play key roles in synaptic remodel- 
ing and plasticity. In this regard, it is worth noting that Tyro 
3 expression in the adult brain is neuronal and is found 
in structures, such as the hippocampus and olfactory bulb, 
notable for their activity-dependent plasticity (Lai and 
Lemke, 1991; Lai et al., 1994). Of particular interest is the 
preliminary observation that Tyro 3 is primarily localized 
to the processes of central nervous system neurons (C. L., 
unpublished data). Finally, the up-regulated expression 
of protein S in reactive Schwann cells and astrocytes is 
consistent with the possibility that protein S is involved in 
growth and remodeling responses to injury, as well as with 
a role for protein S as a classical neurotrophic factor. 
The function of Gas6 is currently unknown, although its 
homology to protein S and its ability to bind Axl suggest 
roles both in clotting and in other systems. It is worth noting 
that Gas6 was cloned on the basis of its dramatic up- 
regulation following growth arrest in a number of cell lines, 
including IMR90 fibroblasts, which also express endoge- 
nous Axl receptors (Manfioletti et al., 1993), indicating that 
autocrine Gas6-Axl  interactions are not sufficient to elicit 
a growth response (at least in some cells) and may instead 
be an intrinsic part of the growth arrest process. It is also 
of interest that the Axl/Ark receptor has recently been 
shown to display homophilic interactions (Bellosta et al., 
1995); the respective roles of Gas6-Axl as opposed to 
AxI-Axl interactions in regulating receptor activation and 
signal transduction remain to be elucidated. 
There is an intriguing similarity between our findings 
and the earlier realization that hepatocyte growth factor, 
which is similar in structure to plasminogen (Tashiro et al., 
1990), also utilizes and activates an RTK, c-Met (Bottaro et 
al., 1991). In fact, recently described angiostatic activities 
of a plasminogen fragment may also be attributable to its 
binding to a specific receptor on endothelial cells (O'Reilly 
et al., 1994). The structural similarities between hepato- 
cyte growth factor and plasminogen, the previous findings 
that thrombin can bind and activate a specific G protein- 
coupled cell surface receptor, and our findings that the 
protein S-related anticoagulant factors bind and activate 
members of a family of RTKs demonstrate together that we 
are far from a complete understanding of the long-studied 
proteins involved in regulating coagulation cascades and 
open a wide variety of unexpected areas for investigation. 
Factors critical for the regulation of coagulation may also 
be exploited in unrelated pathways, in systems such as 
the nervous system. 
Experimental Procedures 
Preparation of Conditioned Medium 
ABAE cells were conditioned in defined medium (Zhan et ai., 1987), 
which was subsequently clarified by centrifugation, brought o 1 mM 
PMSF and 0.14 U/ml aprotinin (both from Sigma Chemical), concen- 
trated 10-fold with 3000 MWCO membranes (Amicon), and stored at 
-80oC. 
Tyrosine Phosphorylation Assays 
Rat2 fibroblasts tably transfected with a Tyro 3-expressing plasmid 
(Lai et al., 1994) were plated 4-5 days before use and serum-starved 
for 3 hr in DMEM prior to the indicated treatments for 5 min at 37°C. 
The cells were then lysed in 1% NP-40 in PBS containing 1 mM PMSF, 
0.14 U/ml aprotinin, 1 mM EDTA, and 1 mM sodium orthovanadate. 
The lysatas were immunoprecipitated with a phosphotyrosine-specific 
monoclonal antibody conjugated to agarose (4G10; Upstate Biotech- 
nologies) and immunoblotted with a polyclonal antiserum (1:4000) spe- 
cific for Tyro 3 (Lai et al., 1994), Following incubation of the blots 
with HRP-conjugated goat anti-rabbit antibodies (Caltag), bands were 
visualized by ECL (Amersham). Blocking assays were performed by 
preincubating with soluble receptor-Fc at indicated concentrations for 
30 rain at 37°C prior to addition to cells. 
Production and Purification of Soluble Tyro 3-Fc, TrkB-Fc, 
and AxI-Fc 
The TrkB-Fc, Tyro 3-Fc, and AxI-Fc proteins resulted from the fusion 
of the ectodomains of rat TrkB, mouse Tyro 3, and mouse Axl to a 
spacer with the sequence Gly-Pro-Gly, followed by the hinge, CH2, 
and CH3 regions of human IgG1, beginning with the residues Glu-Pro- 
Lys, as described (Davis et al., 1994). Tyro 3--Fc and AxI-Fc proteins 
were produced as serum-free supernatants from transiently trans- 
fected COS cells. TrkB-Fc and Tyro 3-Fc were also produced in 
Spodoptera frugiperda SF-21AE cells via recombinant baculovirus in- 
fection performed by standard methods (O'Reilly et al., 1992). Soluble 
receptors from either COS- or baculovirus-derived material were puri- 
fied by protein A-Sepharose (Pharmacia) chromatography. 
BIAcore Analysis 
The binding activity was measured by use of BIAcore biosensor tech- 
nology (Pharmacia Biosensor) (Fagerstam, 1991; Johnsson et al., 
1991). Purified soluble receptors were covalently coupled through pri- 
mary amines to the carboxymethyl dextran layer of a CM5 research 
grade sensor chip (Pharmacia Biosensor), Samples to be assayed for 
binding to the chip were brought to a final concentration of 2 I~g/ml 
dextran (ICN Biochemicals; MWav, 67,000 g/tool) and 0.0050/0 P20 
surfactant. Aliquots of 40 ~1 were injected across the immobilized sur- 
faces at a flow rate of 5 p~l/min, and the receptor binding was monitored 
for 8 min. The binding activity (in RUs) was measured as the difference 
between a baseline value determined 30 s prior to the sample injection 
and a measurement taken at 30 s postinjection. Regeneration of the 
surface was accomplished with one 12 p.I pulse of 3 M MgCI2 (Tyro 
3) or Actisep elution medium. Specific binding was evaluated by incu- 
bating the samples with 10 or 25 p.g/ml of Tyro 3-Fc, AxI-Fc, or TrkB- 
Fc prior to assaying the binding activity. 
Growth and Transformation Assays in NIH 3T3 
and BAF-3 Cells 
Stable transfections of NIH 31"3 cells were performed as previously 
described (Glass et al., 1991). The chimeric receptor EGFR-Tyro 3 
was derived from the ectodomain of human EGFR fused to the trans- 
membrane and cytoplasmic domain of Tyro 3. The Tyro 3-TrkC chime- 
ric receptor was derived from fusion of the first 455 amino acids of 
Tyro 3 to the transmembrane and cytoplasmic domains of rat TrkC. 
The expression plasmid encoding human protein S, pD5-hPS, has 
been described previously (Nelson and Long, 1992). Transformation 
assays involving cotransfection of Tyro 3-TrkC constructs utilized 5 
p.g of receptor expression plasmid, 1 p.g or 5 p.g of protein S expression 
plasmid, 500 ng of LTR-neo plasmid to confer G418 resistance, and 
sufficient human placental genomic DNA to bring the total DNA con- 
centration to 30 I~g per transfection. Transformation and survival 
assays in NIH 3T3 cells were carried out as previously described (Ip 
et al., 1993b), with the exception that survival assays of cells cotrans- 
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fected with Tyro 3-TrkC and protein S vectors were cultured in defined 
medium in the presence or absence of 1 mM menadione sodium bisul- 
fite (Sigma Chemical), a water-soluble vitamin K analog. BAF-3 cells, 
grown in RPMI containing 1 ng/ml IL-3, 10% FBS, and antibiotics were 
transfected with l inearized plasmid by electroporation (200 V, 960 I~F) 
and selected in growth medium plus 400 ~g/ml G418 (GIBCO BRL). 
For growth assays in BAF-3 cells, cells were washed three times with 
RPMI and plated in 96-well dishes at a density of 10,000 cells per well 
in 50 p.I of RPMI, together with 50 I~1 of the indicated additions at a 
2 x concentration in RPMI. The number of viable cells was assessed 
after 3 days by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) as described (Ip et al., 1992). 
Receptor-Based Affinity Purification of Tyro 3 
and Axl Ligands 
For receptor-based affinity purification of the Tyro 3 ligand, 1.5 mg 
of Tyro 3-Fc was cress-linked to a 1 ml HiTrap column (Pharmacia) 
according to the instructions of the manufacturer, with >90% effi- 
ciency. The column was equilibrated in PBS, and 15 ml of FBS then 
loaded at 0.5 ml/min, The column was washed with PBS until OD28o 
<0.01 was seen in the eluate and then was washed with approximately 
6 column vol of 20 mM HEPES (pH 7.4) containing 0.5 M NaCI. Purified 
ligand was then eluted from the column with 10 mM glycine (pH 2.5) 
containing 250 mM NaCI. Affinity purification of the Axl ligand was 
performed as above, except that only 150 p_g of AxI-Fc was cross- 
linked to the HiTrap column and that the PBS-equilibrated column was 
loaded with 500 ml of 10 x concentrated serum-free ABAE conditioned 
medium at 0,5 ml/min. 
Peptide Sequencing of Affinity-Purified Tyro 3 
and Axl Ligands 
Protein (3 I~g) resulting from either the Tyro 3 or Axl affinity purification 
was concentrated to 100 Id, separated by SDS-PAGE, transferred to 
a PVDF (Bio-Rad) membrane, and visualized by Ponceau S staining. 
Membrane fragments containing the protein bands were destained, 
placed in 0.6 ml of 0.1 mM Tris-HCI (pH 8.0), 50°/o 2-propanol to which 
10 p_l of 4-vinylpyridine and 5 p.I of tributylphosphine (Aldrich) were 
added to reduce and pyridylethylate cysteine residues. After 1 hr of 
incubation, the membrane pieces were washed in 50% propanol and 
digested for 15 hr with 1:10 ratio of trypsin in 20 Id of 0.1 M Tris-HCI 
(pH 8.0) containing 1% Triton X-100 (Calbiochem) and 10% acetoni- 
trile. The supernatant was diluted three times with 2% TFA, and the 
peptides released from the membrane were separated by reverse 
phase chromatography on a 0.8 mm x 250 mm C18 column (LC 
Packings), eluted directly onto Beckman sequencing membranes, and 
sequenced on an ABI Procise protein sequencer, 
Production of Recombinant Human Protein S 
COS cells, transiently transfected with pD5-hPS (encoding human pro- 
tein S) or with empty vector, were cultured for 3 days in serum-free 
defined medium supplemented with I mM sodium menadione bisulfite, 
and the clarified culture supernatants were then concentrated 10-fold. 
Protein S concentration was estimated by comparison to purified hu- 
man protein S (Haematologic Technologies) on nonreducing immu- 
noblots probed with a monoclonal antibody to protein S (AHPS 5091 ; 
Haematologic Technologies). 
Northern Blot Analysis 
Northern blot analysis was done as previously described (Ip et al., 
1993a), utilizing a randomly labeled PCR probe corresponding to 
amino acids 267-370 of mouse protein S or a DNA fragment corre- 
sponding to amino acids 132-694 of mouse Tyro 3. 
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